ARHGDIB

Across TCGA pan-cancer cohorts, ARHGDIB Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ARHGDIB data layer compared with 23 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher ARHGDIB Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ARHGDIB expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LUSC, UCEC, and SKCM are the cancer types where ARHGDIB Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	DFS	Median	All	0.079	0.792	<.001	24	view →
UCEC	DFS	Median	All	1.000	0.628	.022	6	view →
SKCM	OS	Median	All	0.120	0.342	.029	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

ARHGDIB–LUSC (DFS)

Open the LUSC breakdown →